173 related articles for article (PubMed ID: 34859337)
21. Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma.
Barta SK; Jain R; Mazumder A; Carter J; Almanzar L; Browne R; Shahnaz S; Elkind R; Kaminetzky D; Battini R; Derman O; Kornblum N; Verma A; Braunschweig I
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):650-657. PubMed ID: 28684379
[TBL] [Abstract][Full Text] [Related]
22. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing.
Admiraal R; van Kesteren C; Jol-van der Zijde CM; van Tol MJ; Bartelink IH; Bredius RG; Boelens JJ; Knibbe CA
Clin Pharmacokinet; 2015 Apr; 54(4):435-46. PubMed ID: 25466602
[TBL] [Abstract][Full Text] [Related]
24. High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma.
Ali MO; Al Hadidi S
Transplant Cell Ther; 2022 Sep; 28(9):572-580. PubMed ID: 35750284
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
[TBL] [Abstract][Full Text] [Related]
26. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
27. [Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia].
Matsuyama T; Kato K; Hanada R; Kawa K; Okamura J; Tsuchida M; Kigasawa H; Watanabe A; Hamamoto K; Kudoh T; Sano K; Ohira M;
Rinsho Ketsueki; 2002 Jul; 43(7):527-37. PubMed ID: 12229121
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Stem Cell Transplant Eligibility in Recipients with Oral Foci of Infection: Appropriate Conditioning Regimens.
Boga C; Sisli SN; Bahar AR; Tamer Y; Kasar M; Bascil S; Ozdogu H; Asma S; Demiroglu YZ; Yeral M
Exp Clin Transplant; 2023 Aug; 21(8):691-700. PubMed ID: 37341460
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Fludarabine, Melphalan and Total Body Irradiation as a Reduced Intensity Conditioning Regimen in Matched Donor Allogeneic Peripheral Blood Stem Cell Transplantation.
Modi D; Chi J; Kim S; Deol A; Ayash L; Ratanatharathorn V; Uberti JP
Transplant Cell Ther; 2021 Aug; 27(8):665.e1-665.e7. PubMed ID: 33991722
[TBL] [Abstract][Full Text] [Related]
30. Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI.
Yamada Y; Ikegawa S; Najima Y; Atsuta Y; Konuma R; Adachi H; Wada A; Kishida Y; Konishi T; Nagata A; Kaito S; Nagata R; Noguchi Y; Marumo A; Mukae J; Inamoto K; Toya T; Igarashi A; Kobayashi T; Sakamaki H; Ohashi K; Doki N
Int J Hematol; 2022 Feb; 115(2):244-254. PubMed ID: 34652634
[TBL] [Abstract][Full Text] [Related]
31. The incidence of severe oral mucositis in patients undergoing different conditioning regimens in haematopoietic stem cell transplantation.
Nakagaki M; Kennedy GA; Gavin NC; Clavarino A; Whitfield K
Support Care Cancer; 2022 Nov; 30(11):9141-9149. PubMed ID: 36008731
[TBL] [Abstract][Full Text] [Related]
32. Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study.
McDonald GB; Evans AT; McCune JS; Schoch G; Ostrow JD; Gooley TA
Lancet Haematol; 2016 Nov; 3(11):e516-e525. PubMed ID: 27968820
[TBL] [Abstract][Full Text] [Related]
33. Phase 1 Study of the Combination of Escalated Total Marrow Irradiation Using Helical Tomotherapy and Fixed High-Dose Melphalan (140 mg/m²) Followed by Autologous Stem Cell Transplantation at First Relapse in Multiple Myeloma.
Cailleteau A; Maingon P; Choquet S; Bourdais R; Antoni D; Lioure B; Hulin C; Batard S; Llagostera C; Guimas V; Touzeau C; Moreau P; Mahé MA; Supiot S
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):677-685. PubMed ID: 36174802
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
[TBL] [Abstract][Full Text] [Related]
35. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.
Clark SM; Clemmons AB; Schaack L; Garren J; DeRemer DL; Kota VK
J Oncol Pharm Pract; 2016 Jun; 22(3):416-22. PubMed ID: 25956421
[TBL] [Abstract][Full Text] [Related]
36. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Nieto Y; Valdez BC; Thall PF; Ahmed S; Jones RB; Hosing C; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Alousi A; Shah N; Bashir Q; Liu Y; Oki Y; Hagemeister F; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1914-20. PubMed ID: 26071868
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients.
Nijstad AL; Nierkens S; Lindemans CA; Boelens JJ; Bierings M; Versluys AB; van der Elst KCM; Huitema ADR
Br J Clin Pharmacol; 2021 Aug; 87(8):3218-3226. PubMed ID: 33444472
[TBL] [Abstract][Full Text] [Related]
38. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM
Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
[TBL] [Abstract][Full Text] [Related]
39. Y
Voegeli M; Rondeau S; Berardi Vilei S; Lerch E; Wannesson L; Pabst T; Rentschler J; Bargetzi M; Jost L; Ketterer N; Bischof Delaloye A; Ghielmini M
Hematol Oncol; 2017 Dec; 35(4):576-583. PubMed ID: 27677906
[TBL] [Abstract][Full Text] [Related]
40. Melphalan 140 mg/m
Auner HW; Iacobelli S; Sbianchi G; Knol-Bout C; Blaise D; Russell NH; Apperley JF; Pohlreich D; Browne PV; Kobbe G; Isaksson C; Lenhoff S; Scheid C; Touzeau C; Jantunen E; Anagnostopoulos A; Yakoub-Agha I; Tanase A; Schaap N; Wiktor-Jedrzejczak W; Krejci M; Schönland SO; Morris C; Garderet L; Kröger N
Haematologica; 2018 Mar; 103(3):514-521. PubMed ID: 29217776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
